<p class='bwalignc'> <i>-- Prophylactic regimens resulted in low single-digit annualized bleeding rates --</i> </p> <p class='bwalignc'> <i>-- Median dosing interval was 14 days in the individualized interval prophylaxis arm during the last 6 months on study --</i> </p> <p class='bwalignc'> <i>-- Greater than 90% of bleeding episodes were controlled by a single injection of rFIXFc --</i> </p> <p class='bwalignc'> <i>-- No patients developed inhibitors to rFIXFc --</i> </p> <p class='bwalignc'> <i>-- The primary efficacy and safety objectives were met and Biogen Idec plans to submit a BLA to US FDA in first half 2013 --</i> </p>

Wednesday, September 26, 2012

BIOGEN IDEC AND SOBI ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING LONG-LASTING RECOMBINANT FACTOR IX FC FUSION PROTEIN IN HEMOPHILIA B07:30 EDT Wednesday, September 26, 2012
WESTON, Mass. and STOCKHOLM, Sweden (Business Wire) -- Biogen
Idec (NASDAQ: BIIB) and Swedish
Orphan Biovitrum (Sobi) (STO: SOBI) today announced positive results
from B-LONG, a clinical study that evaluated a new long-lasting clotting
factor candidate in people with hemophilia B. Hemophilia B is a rare
inherited disorder that impairs blood coagulation.
Top-line results from B-LONG, a global, multi-center, Phase 3 clinical
study of the companies' long-lasting recombinant Factor IX Fc fusion
protein (rFIXFc), showed that rFIXFc was effective in the control and
prevention of bleeding, routine prophylaxis, and perioperative
management. Recombinant FIXFc was generally well-tolerated. Additional
analyses of the B-LONG study are ongoing and the companies anticipate
presenting further results at a future scientific meeting.
Biogen Idec plans to submit a Biologics License Application (BLA) to the
U.S. Food and Drug Administration (FDA) in the first half of 2013.
Consistent with guidelines published by the European Medicines Agency
(EMA) that require a study in children less than 12 years of age prior
to filing, Biogen Idec and Sobi expect to file a Marketing Authorization
Application with the EMA upon completion of the ongoing Kids B-LONG
study.
“The results of the B-LONG study offer the potential for longer-lasting
protection from bleeding for patients with hemophilia B,” said Glenn
Pierce, M.D., Ph.D., Senior Vice President of Global Medical Affairs and
Chief Medical Officer of Biogen Idec's hemophilia therapeutic area.
“Currently, prophylactic treatment of hemophilia B requires intravenous
injections up to three times a week, which makes the prospect of a
longer-lasting Factor IX therapy very exciting.”
“Our companies are pioneering the application of Fc fusion technology to
extend the half-life of clotting factors. Fc fusion technology utilizes
a naturally-occurring recycling pathway that has been successfully
employed in other therapeutic areas. This approach holds promise for
combining more consistent protection with fewer injections,” said
Geoffrey McDonough, M.D., Chief Executive Officer of Sobi. “The B-LONG
study results are highly encouraging and support the potential use of
this technology in hemophilia B.”
Summary of Key Data from B-LONG
In the B-LONG study, 123 male patients aged 12 years and older were
enrolled. The B-LONG study had four treatment arms: weekly prophylaxis,
individualized interval prophylaxis, episodic treatment and
perioperative management (Arms 1, 2, 3 and 4, respectively).
Overall, 93.5 percent of patients completed the study. Recombinant FIXFc
was generally well-tolerated. No inhibitors to rFIXFc were detected and
no cases of anaphylaxis were reported in any patients, all of whom
switched from commercially-available Factor IX products. One serious
adverse event was assessed to be possibly related to drug by the
investigator. The patient experienced obstructive uropathy in the
setting of hematuria; he continued rFIXFc treatment and the event
resolved with medical management.
The most common adverse events (incidence of ≥5 percent) occurring
outside of the perioperative management arm (i.e., Arms 1, 2 and 3, but
not Arm 4) were nasopharyngitis, influenza, arthralgia (joint pain),
upper respiratory infection, hypertension and headache.
The overall median annualized bleeding rates (including spontaneous and
traumatic bleeds) were 2.95 in the weekly prophylaxis arm, 1.38 in the
individualized interval prophylaxis arm, and 17.69 in the episodic
treatment arm. In the individualized interval prophylaxis arm, the
median dosing interval during the last 6 months on study was 14 days.
Control of bleeding was assessed in all patients who experienced a
bleeding episode during the study. Overall, 90.4 percent of bleeding
episodes were controlled by a single injection of rFIXFc.
Recombinant FIXFc was assessed in the perioperative management of 12
patients undergoing 14 major surgical procedures. The treating
physicians rated the hemostatic efficacy of rFIXFc as excellent or good
in 100 percent of these surgeries.
B-LONG included a pharmacokinetic (PK) analysis of rFIXFc in all
patients in the study. In a protocol-defined subset of patients with
extensive PK sampling, the approximate terminal half-life of rFIXFc was
82 hours compared to 34 hours for BeneFIX® [Coagulation Factor IX
(Recombinant)].
About the B-LONG Study and the rFIXFc Program
B-LONG was a global, open-label, multi-center Phase 3 study that
evaluated the efficacy, safety and pharmacokinetics of
intravenously-injected rFIXFc. The study was designed to evaluate rFIXFc
in the control and prevention of bleeding, routine prophylaxis and
perioperative management in patients with hemophilia B. B-LONG involved
50 hemophilia treatment centers in 17 countries on 6 continents, and is
the largest registrational study conducted in hemophilia B.
The B-LONG study had four treatment arms. In Arm 1 (weekly prophylaxis;
n=63), patients were treated weekly with a starting dose of 50 IU/kg,
which was adjusted to maintain trough factor levels sufficient to
prevent bleeding. In Arm 2 (individualized interval prophylaxis; n=29),
patients were treated with 100 IU/kg, at an initial interval of 10 days,
which was subsequently individualized to maintain trough factor levels
sufficient to prevent bleeding. In Arm 3 (episodic treatment; n=27),
patients received rFIXFc episodic treatment as needed for bleeding. In
Arm 4 (perioperative management; n=12 patients), rFIXFc was evaluated in
the surgical setting; 8 patients in the surgery arm were also enrolled
in other treatment arms.
The primary efficacy and safety measures were the annualized bleeding
rate and the incidence of adverse events and inhibitor development in
patients studied for up to 77 weeks. Secondary endpoints included
response to treatment of bleeding episodes and the pharmacokinetics of
rFIXFc versus BeneFIX®.
Ongoing clinical studies of rFIXFc include the Kids B-LONG and the
B-YOND studies. Kids B-LONG is a Phase 3, open-label study in previously
treated children with hemophilia B under age 12, which is actively
recruiting patients. B-YOND is a long-term open-label extension study
for patients who completed the B-LONG study or who complete the Kids
B-LONG study.
About the Fc Fusion Technology Platform
Recombinant FIXFc is a clotting factor developed using Biogen Idec's
novel and proprietary monomeric Fc fusion technology, which makes use of
a natural pathway to recycle rFIXFc in circulation and enable it to
remain in the body longer. With this technology, rFIXFc is designed to
provide long-lasting protection from bleeding and reduce the treatment
burden associated with hemophilia B, which currently requires more than
100 injections annually for prophylaxis with commercially-available
Factor IX products. Fc fusion technology is used in seven FDA-approved
products for the long-term treatment of chronic diseases including
rheumatoid arthritis, psoriasis and platelet disorders.
Using the same Fc fusion technology, Biogen Idec and Sobi are also
developing a long-lasting recombinant Factor VIII Fc fusion protein
(rFVIIIFc) for the control and prevention of bleeding episodes and
routine prophylaxis in hemophilia A. Top-line results from the A-LONG
study are expected later this year. For more information on Biogen
Idec's hemophilia research programs, visit www.biogenidechemophilia.com.
About Hemophilia B
Hemophilia B is a rare, inherited disorder in which the ability of a
person's blood to clot is impaired. Hemophilia B occurs in about one in
25,000 male births annually and is caused by having substantially
reduced or no Factor IX activity, which is needed for normal blood
clotting. People with hemophilia B therefore need injections of Factor
IX to restore the coagulation process and prevent frequent bleeds that
could otherwise lead to pain, irreversible joint damage and
life-threatening hemorrhages. The Medical and Scientific Advisory
Council of the National Hemophilia Foundation recommends prophylaxis as
the optimal therapy for people with severe hemophilia B. Currently,
prophylaxis in hemophilia B typically requires injections up to three
times per week to maintain a sufficient circulating level of clotting
factor.
About the Biogen Idec and Sobi Collaboration
Biogen Idec and Sobi are partners in the development and
commercialization of rFIXFc and rFVIIIFc. Biogen Idec leads development,
has manufacturing rights, and has commercialization rights in North
America and all other regions excluding the Sobi territory. Sobi has the
right to opt in to assume final development and commercialization in
Europe including Russia, the Middle East and Northern Africa.
About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers,
develops and delivers to patients worldwide innovative therapies for the
treatment of neurodegenerative diseases, hemophilia and autoimmune
disorders. Founded in 1978, Biogen Idec is the world's oldest
independent biotechnology company. Patients worldwide benefit from its
leading multiple sclerosis therapies, and the company generates more
than $5 billion in annual revenues. For product labeling, press releases
and additional information about the company, please visit www.biogenidec.com.
About Sobi
Sobi is an international healthcare company dedicated to bringing
innovative therapies and services to improve the lives of rare disease
patients. The product portfolio is primarily focused on inflammation and
genetic diseases, with three late stage biological development projects
within hemophilia and neonatology. Sobi also markets more than 40
products for companies in the specialty and rare disease space. In 2011,
Sobi had revenues of SEK 1.9 billion and around 500 employees. The share
(STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is
available at www.sobi.com.
Safe Harbor
This press release contains forward-looking statements, including
statements about the development and commercialization of long-lasting
hemophilia therapies and regulatory filings. These statements may be
identified by words such as "believe," "expect," "may," "plan," "will"
and similar expressions, and are based on the companies' current beliefs
and expectations. Drug development and commercialization involve a high
degree of risk. Factors which could cause actual results to differ
materially from the companies' current expectations include the risk
that unexpected concerns may arise from additional data or analysis,
regulatory authorities may require additional information or further
studies, or may fail to approve our drug candidates, or the companies
may encounter other unexpected hurdles. For more detailed information on
the risks and uncertainties associated with Biogen Idec's drug
development and commercialization activities, please review the Risk
Factors section of Biogen Idec's most recent annual or quarterly report
filed with the Securities and Exchange Commission. Any forward-looking
statements speak only as of the date of this press release and the
companies assume no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.
The information above has been published pursuant to the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on September 26, 2012
at 1:30 p.m. CET.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50418653&lang=en
Biogen Idec Media Contact:Jim Baker, +1-781-464-3260Senior
Manager, Public AffairsorBiogen Idec Investor Relations
Contact:Kia Khaleghpour, +1-781-464-2442Director,
Investor RelationsorSwedish Orphan Biovitrum:Åsa
Stenqvist, +46 8 697 21 88Head of Communications and Investor
Relations

Restrictions

All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. Thomson Reuters is not liable for any errors or delays in Thomson Reuters content, or for any actions taken in reliance on such content. ‘Thomson Reuters’ and the Thomson Reuters logo are trademarks of Thomson Reuters and its affiliated companies.